fda bans tirzepatide 2026 Rules and News for Compounded FDA says shortage of GLP-1

[1] Unlike amphetamine abuse, where drug tolerance necessitates escalating doses to achieve the same effect, tolerance to clinically relevant doses of amphetamine plateaus after the initial titration period, and "drug holidays" (i.e., temporary treatment discontinuation) are not required to prevent the development of tolerance

A Note on FAERS Data and Underreporting The FDA's Adverse Event Reporting System (FAERS) captures spontaneous reports, which represent only a fraction of actual adverse events, estimates suggest under-reporting rates between 90% and 99% for non-serious events

lavocat

Rapid weight loss from taking GLP-1 medications like Ozempic and Wegovy can cause a decrease in muscle mass, lessen bone density, and lower your resting metabolic rate, leading to sarcopenia